SCHEMBL702867

SCHEMBL702867

Cc1nc2cc(OCCN(C)C)ccn2c1-c1ccnc(Nc2ccc(C(=O)Nc3ccccc3N)cc2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 11/20 0.58
IGF1R P08069 7/20 0.58
EGFR P00533 2/20 0.52
ERBB2 P04626 2/20 0.52
CDK1 P06493 1/20 0.48
CDK4 P11802 1/20 0.48
CCNE1 P24864 1/20 0.48
CDK2 P24941 1/20 0.48
HDAC3 O15379 1/20 0.48
ABL1 P00519 1/20 0.48
PDGFRB P09619 1/20 0.48
KDR P35968 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL699060 0.92 HDAC1 (0.61) HDAC1IGF1RCDK4CCNE1CDK2
SCHEMBL700171 0.89 HDAC1 (0.62) HDAC1IGF1RCDK4CCNE1CDK2
SCHEMBL700392 0.88 HDAC1 (0.61) HDAC1IGF1RCDK1CDK4CCNE1
SCHEMBL699248 0.87 IGF1R (0.53) IGF1REGFRERBB2CDK1CDK4
SCHEMBL700335 0.87 HDAC1 (0.58) HDAC1IGF1RCDK2HDAC3ABL1
SCHEMBL701309 0.87 HDAC1 (0.64) HDAC1CDK1CDK4CCNE1CDK2
SCHEMBL12790417 0.87 HDAC1 (0.47) HDAC1IGF1RCDK2HDAC3HDAC2
SCHEMBL700958 0.87 HDAC1 (0.60) HDAC1IGF1RABL1
SCHEMBL7978517 0.86 IGF1R (0.53) IGF1REGFRERBB2CDK1CDK4
SCHEMBL656720 0.85 HDAC1 (0.51) HDAC1IGF1REGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US claimed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US claimed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
WO-2010009155-A2 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC7 HDAC1 1/4885IGF1R 1719/4885EGFR 2330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.